Shots:

• The company reported that all the P-I studies assessing insulin aspart (GL-ASP)- insulin lispro (GL-LIS)- and insulin glargine (GL-GLA) met their primary PK & PD analyses and demonstrated that PK/PD bioequivalence b/w each of the proposed biosimilar and their respective reference compounds
• The safety profiles were comparable b/w each of the three proposed biosimilar and their respective reference compounds
• The company is working to bring biosimilar insulins into clinical practice with the goal of reducing the global burden of diabetes

  | Ref: PR Newswire | Image: Caixin Global